drugset / Trial / NCT05330143
Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is a phase II, multicenter, randomized, blind, placebo-controlled to evaluate the safety, tolerance, efficacy of ASC22 injection in combination with anti-retroviral therapy to treat subjects living with human immunodeficiency virus type 1.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2024-05-15
- Completion
- 2024-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Envafolimab | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | Envafolimab | Monoclonal antibody | 2.5 mg/kg | Subcutaneous |